Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025
January 17, 2025
Biotechnology
-
-
ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation
January 17, 2025
-
HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
January 14, 2025
-
Aditxt’s Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform
January 13, 2025
-
Quantum-Si Launches Platinum® Pro: The End-to-End Solution for Deeper Insights in Proteomics
January 13, 2025
-
Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline
January 8, 2025
-
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
January 7, 2025
-
Predictive Oncology Announces Agreement to be Acquired by Renovaro
January 6, 2025
-
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
January 3, 2025
-
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®
January 3, 2025
-
BrainStorm Issues 2024 Letter to Shareholders
December 30, 2024
-
Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering
December 20, 2024
-
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)
December 20, 2024
-
INOVIO Announces Pricing of $30 Million Public Offering
December 13, 2024
-
Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma
December 12, 2024
-
Sequire Spotlight Presents: BioHarvest Sciences (BHST) – Global Leader in Plant Cell Technology
December 3, 2024